Introduction {#S0001}
============

In their 2011 report, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) introduced categorizing patients with COPD based on their symptom burden and exacerbation risk.[@CIT0001] In this schema, GOLD category A patients have a low symptom burden and a low risk of exacerbations.[@CIT0002] A low symptom burden is defined as a COPD Assessment Test (CAT)[@CIT0003] score of \<10 or a modified Medical Research Council (mMRC)[@CIT0004] score of \<2,[@CIT0002] and a low risk of exacerbations is defined as no exacerbations or one moderate exacerbation (i.e., not leading to hospitalization) in the previous year.[@CIT0002]

The GOLD 2020 report suggests that the GOLD categories may be used to guide initial pharmacological treatments for patients, with the most recent strategy proposing that GOLD category A patients are treated with a single short-acting bronchodilator or a single long-acting bronchodilator when starting pharmacological treatment.[@CIT0002] Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) plus a long-acting β~2~-agonist (LABA) as an initial therapy is recommended for highly symptomatic GOLD category D patients who have a high risk of exacerbations, and may be considered as an initial therapy for GOLD category B patients who have a low risk of exacerbations and severe breathlessness.[@CIT0002] Dual LAMA/LABA therapy is also recommended as a step-up treatment from long-acting bronchodilator monotherapy for patients with persistent breathlessness or exercise limitation, and for patients with persistent exacerbations, particularly those with low blood eosinophil levels.[@CIT0002]

Many Phase III studies investigating LAMA/LABA fixed-dose combinations (FDCs) have excluded patients with a low symptom burden, for example, those defined by an mMRC score of \<2,[@CIT0005]--[@CIT0008] thereby excluding GOLD category A patients.[@CIT0002] The PINNACLE Phase III clinical trial program has demonstrated the efficacy and safety of the dual LAMA/LABA FDC glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI; Bevespi Aerosphere^®^), formulated using co-suspension delivery technology, in patients with moderate-to-very severe airflow obstruction who were not required to have a high symptom burden at study entry.[@CIT0009]--[@CIT0011] Therefore, this allowed a pooled analysis of PINNACLE-1, -2, and -4 to evaluate the effects of GFF MDI on lung function and safety in GOLD 2017[@CIT0012] category A patients with COPD who had moderate-to-very severe airflow obstruction. We hypothesized that this patient population would benefit from dual LAMA/LABA therapy. To our knowledge, the efficacy and safety of a LAMA/LABA FDC has rarely been studied in GOLD category A patients.

Materials and Methods {#S0002}
=====================

Study Design {#S0002-S2001}
------------

PINNACLE-1, -2, and -4 (NCT01854645, NCT01854658, and NCT02343458) were Phase III randomized, double-blind, placebo-controlled, parallel-group, multicenter studies ([Figure 1](#F0001){ref-type="fig"}).[@CIT0009],[@CIT0011] PINNACLE-1 was conducted in the USA, Australia, and New Zealand; PINNACLE-2 was conducted in the USA; and PINNACLE-4 was conducted in Asia, Europe, and the USA.Figure 1Study Flow Diagram for GOLD Category A Patients in PINNACLE-1, -2, and -4.**Notes:** N indicates the number of GOLD category A patients in each treatment arm. ^a^The open-label tiotropium bromide 18 μg DPI treatment arm was only included in PINNACLE-1.**Abbreviations:** DPI, dry-powder inhaler; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; MDI, metered dose inhaler.

Patients received 24 weeks of treatment with GFF MDI 18/9.6 µg, glycopyrrolate (GP) MDI 18 µg, formoterol fumarate (FF) MDI 9.6 µg, or placebo MDI twice daily in all studies. PINNACLE-1 included an additional treatment arm in which patients received open-label tiotropium bromide 18 µg dry-powder inhaler (DPI) once daily (Spiriva^®^ HandiHaler^®^). Patients who were receiving a stable dose of inhaled corticosteroid (ICS) at screening were permitted to continue its use throughout the studies.

Patients provided written informed consent prior to screening, and the studies were conducted in accordance with Good Clinical Practice, including the Declaration of Helsinki and the International Council for Harmonisation. The protocols were approved by local institutional review boards, as previously reported for each study ([[Table S1](http://www.dovepress.com/get_supplementary_file.php?f=229794.docx)]{.ul}).[@CIT0009],[@CIT0011]

Patient Population {#S0002-S2002}
------------------

Key inclusion and exclusion criteria have been previously described.[@CIT0009],[@CIT0011] Briefly, patients were current or former smokers (≥10 pack-years) who were 40--80 years of age, with an established clinical history of COPD as defined by the American Thoracic Society/European Respiratory Society.[@CIT0013] Patients were required to have a post-bronchodilator forced expiratory volume in 1 second (FEV~1~)/forced vital capacity ratio of \<0.70, and an FEV~1~ of \<80% predicted normal (FEV~1~ ≥750 mL if \<30% predicted normal).

There were no inclusion criteria related to baseline symptom burden or exacerbation history. Patients were categorized as GOLD A if they had a CAT score of \<10 at screening, and either no exacerbations or one exacerbation that did not lead to hospitalization in the previous year.[@CIT0012]

Lung Function Outcomes {#S0002-S2003}
----------------------

Subgroup analysis by GOLD category was performed in the pooled intent-to-treat (ITT) population for the lung function endpoints of change from baseline in morning pre-dose trough FEV~1~ (primary endpoint in all studies), and peak change from baseline in FEV~1~ within 2 hrs post-dose (secondary endpoint in all studies), which were the only endpoints that were pre-specified in the integrated analyses. Baseline FEV~1~ was defined as the mean of all evaluable 60- and 30-min pre-dose values on Day 1 of treatment.

Safety {#S0002-S2004}
------

Treatment-emergent adverse events (TEAEs) were monitored throughout the studies, and a subgroup analysis of TEAEs by GOLD category was performed for the pooled studies.

Statistical Analyses {#S0002-S2005}
--------------------

The pooled ITT population included all patients who were randomized and received any amount of study treatment, analyzed according to treatment assigned. The pooled safety population included patients who were randomized and received any amount of study treatment, analyzed according to treatment received. The tiotropium DPI treatment arm from the PINNACLE-1 study was not included in these pooled analyses since this treatment arm was only present in one of the three studies, tiotropium was administered open-label, and only a small number of GOLD category A patients were included. However, lung function data for GOLD category A patients in the PINNACLE-1 study, including the open-label tiotropium DPI arm, are shown in [[Table S2](http://www.dovepress.com/get_supplementary_file.php?f=229794.docx)]{.ul}.

The analyses of lung function by GOLD category were specified in an integrated statistical analysis plan that was developed after the reporting of data from PINNACLE-1 and -2, but prior to the unblinding of PINNACLE-4. All analyses were interpreted according to a nominal significance level of 0.05. No adjustment for multiplicity was applied, as type I error was controlled within individual studies. The lung function endpoints were analyzed using a linear repeated measures model with an unstructured covariance matrix, which included the following covariates: baseline FEV~1~, percent reversibility to albuterol sulfate, study (PINNACLE-1/PINNACLE-2/PINNACLE-4), treatment, visit, and treatment-by-visit interaction.

Results {#S0003}
=======

Baseline Demographics and Clinical Characteristics {#S0003-S2001}
--------------------------------------------------

Of the 4983 patients who were included in the pooled ITT population, 729 (14.6%) were GOLD category A, 3693 (74.1%) were GOLD category B, 73 (1.5%) were GOLD category C, and 473 (9.5%) were GOLD category D (15 patients had missing data). The pooled GOLD category A safety population included 730 patients (one additional patient in the FF MDI treatment arm; this patient had entered multiple studies and was included only for the first of these in the ITT population, but was included for both instances in the safety population, as these periods were not overlapping).

The mean age (standard deviation \[SD\]) of GOLD category A patients in the pooled ITT population was 65.5 (7.6) years. The majority of patients were male (72.7%), White (59.4%), and 65.4% had moderate airflow obstruction (post-bronchodilator FEV~1~ 50--\<80% predicted). Approximately one third (36.1%) of patients were Asian or were current smokers (32.8%; [Table 1](#T0001){ref-type="table"}). The mean total CAT score (SD) was 6.5 (2.2), and the mean COPD duration (SD) was 6.0 (5.7) years. Despite being GOLD category A, 30.2% of patients were using an ICS at baseline and were allowed to continue its use throughout the study. Baseline demographics and clinical characteristics were generally similar across treatment groups ([Table 1](#T0001){ref-type="table"}).Table 1Baseline Demographic and Clinical Characteristics for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (ITT Population)GFF MDI 18/9.6 µg (N=217)GP MDI 18 µg (N=195)FF MDI 9.6 µg (N=204)Placebo MDI (N=113)Overall (N=729)Mean age (SD), years65.7 (7.2)64.9 (8.0)65.2 (7.8)66.5 (7.4)65.5 (7.6)Male, n (%)157 (72.4)149 (76.4)148 (72.5)76 (67.3)530 (72.7)Mean BMI (SD), kg/m^2^26.1 (5.3)26.0 (5.1)25.5 (4.9)25.9 (5.6)25.9 (5.2)Race, n (%) White131 (60.4)118 (60.5)115 (56.4)69 (61.1)433 (59.4) Asian79 (36.4)65 (33.3)81 (39.7)38 (33.6)263 (36.1) Other7 (3.2)12 (6.2)8 (3.9)6 (5.3)33 (4.5)Mean total CAT score^a^ (SD)6.5 (2.2)6.4 (2.2)6.5 (2.1)6.7 (2.3)6.5 (2.2)Used ICS at baseline, n (%)57 (26.3)59 (30.3)67 (32.8)37 (32.7)220 (30.2)Current smoker, n (%)76 (35.0)66 (33.8)58 (28.4)39 (34.5)239 (32.8)Mean number of pack-years smoked^b^ (SD)47.5 (26.6)43.6 (25.1)45.9 (23.7)45.0 (24.9)45.6 (25.1)COPD severity^c^, n (%) Mild (FEV~1~ ≥80% predicted)3 (1.4)4 (2.1)4 (2.0)3 (2.7)14 (1.9) Moderate (FEV~1~ 50--\<80% predicted)154 (71.0)123 (63.1)129 (63.2)71 (62.8)477 (65.4) Severe (FEV~1~ 30--\<50% predicted)58 (26.7)61 (31.3)68 (33.3)38 (33.6)225 (30.9) Very severe (FEV~1~ \<30% predicted)2 (0.9)7 (3.6)3 (1.5)1 (0.9)13 (1.8)Mean COPD duration^d^ (SD), years5.8 (5.3)6.3 (6.2)5.6 (5.3)6.4 (6.3)6.0 (5.7)[^1][^2]

Change from Baseline in Morning Pre-Dose Trough FEV~1~ {#S0003-S2002}
------------------------------------------------------

In GOLD category A patients, GFF MDI significantly improved change from baseline in morning pre-dose trough FEV~1~ at Week 24 versus GP MDI (least squares mean \[LSM\] difference 54 mL; *p*=0.0053), versus FF MDI (LSM difference 62 mL; *p*=0.0013), and versus placebo MDI (LSM difference 188 mL; *p*\<0.0001). The findings over 24 weeks were consistent with those at Week 24, with significant improvements for GFF MDI versus GP MDI (LSM difference 62 mL), FF MDI (LSM difference 59 mL), and placebo MDI (LSM difference 183 mL; all *p*\<0.0001; [Table 2](#T0002){ref-type="table"}). The benefits of GFF MDI over monocomponents and placebo MDI were observed at all time points ([Figure 2](#F0002){ref-type="fig"}).Table 2Lung Function Endpoints for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (ITT Population)GFF MDI 18/9.6 µgGP MDI 18 µgFF MDI 9.6 µgPlacebo MDI**Baseline FEV~1~, L**n216195204113Mean (SD)1.393 (0.466)1.345 (0.507)1.323 (0.483)1.329 (0.491)**Change from baseline in morning pre-dose trough FEV~1~, mL***At Week 24*n19717717896LSM (SE)106 (13.4)52 (14.2)44 (14.1)--82 (19.0)Treatment difference for GFF MDI vs monocomponents and placebo MDILSM (95% CI)NA54 (16, 92)\*62 (25, 100)\*188 (143, 234)\*\**Over 24 weeks*n214191199107LSM (SE)134 (10.1)72 (10.7)75 (10.6)--49 (14.2)Treatment difference for GFF MDI vs monocomponents and placebo MDILSM (95% CI)NA62 (33, 90)\*\*59 (31, 87)\*\*183 (149, 217)\*\***Peak change from baseline in FEV~1~ within 2 hrs post-dose, mL***At Week 24*n19817717996LSM (SE)335 (15.0)210 (15.8)230 (15.7)28 (21.1)Treatment difference for GFF MDI vs monocomponents and placebo MDILSM (95% CI)NA124 (82, 167)\*\*104 (62, 147)\*\*307 (256, 358)\*\**Over 24 weeks*n216195204113LSM (SE)357 (10.9)221 (11.4)275 (11.3)57 (15.1)Treatment difference for GFF MDI vs monocomponents and placebo MDILSM (95% CI)NA136 (106, 167)\*\*83 (52, 113)\*\*300 (264, 336)\*\*[^3][^4] Figure 2Change from Baseline in Morning Pre-dose Trough FEV~1~ for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (ITT Population).**Note:** Error bars represent standard error.**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered dose inhaler.

Peak Change from Baseline in FEV~1~ {#S0003-S2003}
-----------------------------------

GFF MDI improved peak change from baseline in FEV~1~ within 2 hrs post-dose at Week 24 versus GP MDI (LSM difference 124 mL), versus FF MDI (LSM difference 104 mL), and versus placebo MDI (LSM difference 307 mL; all *p*\<0.0001). The findings over 24 weeks were consistent with those at Week 24, with significant improvements reported for GFF MDI versus GP MDI (LSM difference 136 mL), versus FF MDI (LSM difference 83 mL), and versus placebo MDI (LSM difference 300 mL; *p*\<0.0001; [Table 2](#T0002){ref-type="table"}). Furthermore, the benefits of GFF MDI over monocomponents and placebo MDI were observed at all timepoints ([Figure 3](#F0003){ref-type="fig"}).Figure 3Peak Change from Baseline in FEV~1~ Within 2 hrs Post-dose for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (ITT Population).**Note:** Error bars represent standard error.**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered dose inhaler.

Safety {#S0003-S2004}
------

In the GFF MDI group, 56.7% of GOLD category A patients experienced a TEAE throughout the studies, and 11.1% experienced a TEAE related to study treatment, in the opinion of the investigator. The most common TEAEs in the GFF MDI group were upper respiratory tract infection (6.9%) and viral upper respiratory tract infection (6.0%). Sixteen patients (7.4%) had serious TEAEs with GFF MDI, and four patients (1.8%) experienced a serious TEAE related to study treatment, in the opinion of the investigator. The most common serious TEAE was worsening of COPD, which occurred in seven patients (3.2%) in the GFF MDI treatment arm.

A total of 36 patients (4.9%) discontinued from the study early due to TEAEs, with the highest incidence of discontinuations due to TEAEs in the placebo MDI group (7.1%). One death occurred in GOLD category A patients (FF MDI group; probable cardiovascular cause). The TEAE profile of GFF MDI in GOLD category A patients was generally similar to that of the monocomponents and placebo MDI ([Table 3](#T0003){ref-type="table"}), and was consistent with the overall patient population in the PINNACLE studies.[@CIT0009],[@CIT0011]Table 3Summary of TEAEs for the Pooled PINNACLE-1, -2, and -4 Studies in GOLD 2017 Category A Patients (Safety Population)Number of Patients with a TEAE (%) \[Number of TEAEs\]GFF MDI 18/9.6 µg (N=217)GP MDI 18 µg (N=195)FF MDI 9.6 µg (N=205)^a^Placebo MDI (N=113)Overall (N=730)≥1 TEAE123 (56.7) \[244\]106 (54.4) \[274\]112 (54.6) \[248\]70 (61.9) \[164\]411 (56.3) \[930\]TEAEs related to study treatment^b^24 (11.1) \[30\]20 (10.3) \[29\]19 (9.3) \[25\]12 (10.6) \[20\]75 (10.3) \[104\]Serious TEAEs16 (7.4) \[19\]7 (3.6) \[10\]15 (7.3) \[19\]7 (6.2) \[10\]45 (6.2) \[58\]Serious TEAEs related to study treatment^b^4 (1.8) \[4\]3 (1.5) \[4\]01 (0.9) \[1\]8 (1.1) \[9\]TEAEs leading to early discontinuation12 (5.5) \[16\]9 (4.6) \[19\]7 (3.4) \[9\]8 (7.1) \[9\]36 (4.9) \[53\]Deaths001 (0.5)^c^01 (0.1)TEAEs occurring in ≥3% of patients in any treatment arm (preferred term), n (%) \[events\] Viral upper RTI13 (6.0) \[17\]19 (9.7) \[24\]15 (7.3) \[16\]6 (5.3) \[7\]53 (7.3) \[64\] Upper RTI15 (6.9) \[16\]11 (5.6) \[12\]10 (4.9) \[12\]9 (8.0) \[9\]45 (6.2) \[49\] Cough3 (1.4) \[3\]9 (4.6) \[10\]1 (0.5) \[1\]4 (3.5) \[5\]17 (2.3) \[19\] Bronchitis4 (1.8) \[4\]6 (3.1) \[6\]1 (0.5) \[1\]5 (4.4) \[5\]16 (2.2) \[16\] Dyspnea1 (0.5) \[1\]5 (2.6) \[6\]5 (2.4) \[5\]4 (3.5) \[4\]15 (2.1) \[16\] COPD^d^7 (3.2) \[7\]2 (1.0) \[2\]1 (0.5) \[1\]4 (3.5) \[4\]14 (1.9) \[14\] Diarrhea2 (0.9) \[2\]1 (0.5) \[1\]2 (1.0) \[3\]4 (3.5) \[5\]9 (1.2) \[11\] Hypertension02 (1.0) \[2\]2 (1.0) \[2\]5 (4.4) \[5\]9 (1.2) \[9\][^5][^6]

Discussion {#S0004}
==========

This pooled analysis of the PINNACLE-1, -2, and -4 studies evaluated the lung function efficacy and safety of the LAMA/LABA FDC GFF MDI in GOLD category A patients. Consistent with the findings in the overall population, the majority of whom were GOLD category B (74.1%), GFF MDI improved lung function outcomes versus monocomponents and placebo in GOLD category A patients, with a magnitude of improvement that was comparable with the overall population.[@CIT0009],[@CIT0011] Furthermore, improvements with GFF MDI versus placebo for morning pre-dose trough FEV~1~ at Week 24 and over 24 weeks exceeded the suggested minimal clinically important difference of 100 mL (≥183 mL).[@CIT0014] Findings were consistent with a previous pooled analysis of PINNACLE-1 and -2, which showed that lung function benefits with GFF MDI were independent of baseline symptom burden.[@CIT0015] Our findings with GFF MDI are also generally consistent with a pooled post hoc analysis of tiotropium + olodaterol soft mist inhaler versus placebo and tiotropium monotherapy in GOLD category A patients with moderate-to-severe COPD, which also found lung function improvements were similar between GOLD groups.[@CIT0016] The lung function benefits from LAMA/LABA therapy need to be weighed against the known class effects of these bronchodilators.[@CIT0002]

GOLD category A patients have a low symptom burden and low exacerbation risk and, therefore, there is limited capacity for improvements in symptoms, health-related quality of life, and exacerbation outcomes in these patients. Corresponding with this, a previous pooled analysis of the PINNACLE-1 and -2 studies showed that improvements in St George's Respiratory Questionnaire score, rescue medication use, and the rate of moderate/severe COPD exacerbations with GFF MDI versus monocomponents and placebo MDI increased with higher baseline CAT scores.[@CIT0015]

GFF MDI was well tolerated with no new or unexpected safety findings in GOLD category A patients compared with the overall population.[@CIT0009],[@CIT0011] The TEAE profile of GFF MDI was generally comparable to that of the LAMA and LABA monocomponents and placebo MDI.

Conclusion {#S0005}
==========

GFF MDI showed significant improvements in lung function compared with the monocomponent MDIs and placebo MDI and was well tolerated in GOLD category A patients. Improving lung function is a key treatment goal in these patients and, therefore, dual long-acting bronchodilator therapy may be an appropriate alternative treatment option for GOLD category A patients.
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[^1]: **Notes:** ^a^The total score was the sum of eight CAT item scores (range: 0--40). ^b^Number of pack-years smoked = (number of cigarettes per day/20) × number of years smoked. ^c^Based on post-bronchodilator FEV~1~. ^d^GFF MDI 18/9.6 µg, N=216; GP MDI 18 µg, N=195; FF MDI 9.6 µg, N=202; placebo MDI, N=113; overall N=726.

[^2]: **Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; ICS, inhaled corticosteroid; ITT, intent-to-treat; MDI, metered dose inhaler; SD, standard deviation.

[^3]: **Notes:** \**p*\<0.01; \*\**p*\<0.0001.

[^4]: **Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; NA, not applicable; MDI, metered dose inhaler; SD, standard deviation; SE, standard error.

[^5]: **Notes:** ^a^One patient who was included in multiple studies was included in the safety population twice. ^b^Possibly, probably, or definitely related, rated as per investigator's judgment prior to unblinding. ^c^Probable cardiovascular cause during the treatment period. ^d^Worsening of COPD defined as a COPD exacerbation since the patient's last visit. COPD exacerbations were only recorded as an adverse event if they were considered to be a serious TEAE.

[^6]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, glycopyrrolate; MDI, metered dose inhaler; RTI, respiratory tract infection; TEAE, treatment-emergent adverse event.
